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Single dose intrathecal morphine in combination 
with spinal (subarachnoid) local anaesthetic 
injection, providing intraoperative anaesthesia and 
postoperative analgesia, has been utilized for the last 
25 years or more1. However some clinicians view this 
technique as unsafe because of concerns of delayed 
respiratory depression2. The perception of increased 
opioid-related side-effects and lack of titratability of 
analgesia with this technique may lead some clinicians 
to favour systemic opioids, including patient-
controlled analgesia (PCA) and other methods of 
pain relief. It has been argued that all patients given 
intrathecal morphine must be admitted to a high 
dependency or intensive care unit (HDU or ICU) for 
closer nursing observations3, 4.
For more than ten years intrathecal morphine and 
other intrathecal opioids have been popular analgesic 
techniques after caesarean section. Most studies 
RI HIÀFDF\ DQG VDIHW\ DIWHU LQWUDWKHFDO PRUSKLQH
have been conducted in women after caesarean 
section5,6. Fewer studies have reported on the safety 
of this technique in elderly post-surgical patients after 
non-obstetric surgery; for example after urologic, 
orthopaedic, vascular, non-obstetric gynaecological 
and general surgery. Gwirtz et al7 conducted a 
prospective clinical observational study of more than 
5000 patients who received intrathecal opioids for 
analgesia after such operations. They reported a high 
degree of patient satisfaction and a low incidence 
of adverse effects including respiratory depression. 
However, the incidence of respiratory depression in 
their study was 3%, which many would not regard 
as low. The investigators suggested that low-risk 
adult patients less than 70 years of age who received 
intrathecal opioids after non-obstetric surgery could 
be safely managed in a regular hospital ward.
The Royal Adelaide Hospital (RAH) is an adult 
tertiary referral centre of some 700 beds. The RAH 
Acute Pain Service (APS) was established in 1989 to 
provide and supervise advanced analgesic techniques 
for predominantly postoperative patients. The APS 
is a 24-hour service run by anaesthetists. In our 
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SUMMARY
We conducted a retrospective audit of adult non-obstetric patients who had received a single dose of intrathecal 
morphine for postoperative analgesia. These patients were predominantly admitted to a regular postsurgical ward with 
strict hourly nursing observations, treatment protocols in place and supervision by an Acute Pain Service for the first 
24 hours after intrathecal morphine administration. A total of 409 cases were examined for sedation score, incidence 
of respiratory depression and other side-effects, admission to the high dependency or intensive care unit and opioid-
tolerance. Respiratory depression was defined as requiring treatment with naloxone (implying a sedation score of 3 
irrespective of respiratory rate), or a sedation score of 2 with a respiratory rate less than six breaths per minute. The 
patients were predominantly elderly (57.2% were over the age of 70 years) and 84.8% had undergone vascular surgery. 
Of the total of 409 cases, only one case of respiratory depression was observed. A total of 77 patients were admitted 
to high dependency or intensive care unit for various reasons including management of postsurgical complications 
and patient co-morbidities. Our findings suggest that elderly patients who receive intrathecal morphine analgesia can 
be safely managed in a regular postsurgical ward.
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institution, additional opioid administration is strictly 
IRUELGGHQ IRU WKHÀUVWKRXUVDIWHUDGPLQLVWUDWLRQ
of intrathecal morphine, unless approved by the 
APS. We admit patients given intrathecal morphine 
after vascular surgery to our regular vascular unit 
ward, where there are APS-accredited nursing staff 
and strict protocols in place for monitoring and early 
treatment of any adverse effects. However, we plan to
admit other postsurgical patients who have been 
given intrathecal morphine to our HDU or ICU. The 
RAH has a high proportion of elderly patients with 
VLJQLÀFDQWFRPRUELGLWLHVDVZHOODVSDWLHQWVZKRDUH
opioid-tolerant. The aim of this audit was to assess the
incidence of respiratory depression and other 
complications with intrathecal morphine use in our 
institution.
METHOD
Approximately 26,000 RAH APS data sheets 
from March 1989 to December 2003 were retro-
spectively reviewed and the information from patients 
who had been given a single dose of intrathecal 
morphine in combination with spinal (subarachnoid) 
anaesthesia was examined. Patients who were given 
other intrathecal opioids (such as fentanyl and 
pethidine) and patients with in-dwelling intrathecal 
catheters were excluded. 
The information from the APS data sheets was 
reviewed for age and gender of patient, type of 
surgery, dose of intrathecal morphine, sedation 
scores, respiratory depression, ward admitted to after 
the recovery unit and any opioid administration within 
24 hours after intrathecal morphine. Incidence of 
nausea or vomiting and pruritus were also recorded. 
After approval from the hospital Research Ethics
Committee, patients’ medical records were also 
checked to obtain any incomplete data regarding 
intrathecal morphine dose, further opioid administra-
WLRQZLWKLQWKHÀUVWKRXUVDQGZDUGRIGLVFKDUJH
Respiratory depression as an adverse effect of 
intrathecal morphine was of particular interest in this 
audit. Respiratory depression requiring treatment 
ZLWKQDOR[RQHLVGHÀQHGE\WKH$FXWH3DLQ6HUYLFHDV
a sedation score of 3, irrespective of respiratory rate, 
or a sedation score of 2 plus a respiratory rate of less 
than six breaths/minute. Sedation is a more reliable 
early sign of opioid-induced respiratory depression 
than a decrease in respiratory rate (see Discussion). 
The sedation scoring system used at our hospital is 
outlined in Table 1. Any respiratory depression, 
administration of naloxone, further resuscitative
management and transfer to the HDU were also 
noted.
Patients who were opioid-tolerant preoperatively 
and who subsequently received intrathecal morphine 
were of particular interest in this audit. These patients 
ZHUH GHÀQHG DV KDYLQJ UHFHLYHG RSLRLG DJRQLVWV
regularly for at least seven days before their surgery 
DQG ZHUH LGHQWLÀHG IURP WKH $36 GDWD VKHHWV
Information about any additional opioid admin-
LVWUDWLRQ ZLWKLQ WKH ÀUVW  KRXUV DIWHU LQWUDWKHFDO
morphine administration was collected from the 
APS data sheet or the patient’s medical records. 
5HVSLUDWRU\GHSUHVVLRQXVLQJWKHVDPHGHÀQLWLRQDV
above, was also looked for closely.
As elderly patients may have an increased risk of
respiratory depression following intrathecal mor-
phine, patients in this audit were arbitrarily divided
into two age groups; those aged 70 years or more
and those under the age of 70 years. A reduced opioid 
dose for elderly patients is used by the APS regardless 
of the technique involved, for example halving the 
initial bolus dose of PCA morphine to 0.5 mg.
RESULTS
$ WRWDO RI  SDWLHQWV ZHUH LGHQWLÀHG RYHU WKH
13-year period; 272 were male and 137 female (66.5% 
and 33.5% respectively). More than half the patients 
(57.2%) were aged 70 years or older. The majority 
of patients (84.8%) had undergone vascular surgery. 
Table 2 summarizes patient and surgical data.
The doses of intrathecal morphine used ranged 
from 0.05 mg to 0.3 mg; the majority were 0.1 mg, 
0.15 mg or 0.2 mg (22.9%, 30.2%, and 45.3% 
UHVSHFWLYHO\RIDOOGRVHV3DLQVFRUHVZLWKLQWKHÀUVW
24 hours are measured using a verbal numerical 
scale (between 0 to 10), however only 54% of APS 
record sheets provided this information. Table 3 
summarizes the adverse effects recorded following 
administration of intrathecal morphine. 
Only one patient out of the total 409 cases 
developed respiratory depression by our APS criteria 
(0.24%). This was a 74-year-old male with a past 
history of cerebrovascular accidents resulting in 
dysarthria and epilepsy. Preoperatively he was 
managed with an intravenous ketamine infusion 
TABLE 1
Definition of sedation scores
Sedation score Clinical features
0 None
1 Mild, occasionally drowsy, easy to rouse
2 Moderate, constantly drowsy, easy to rouse
3 Severe, somnolent, difficult to rouse
S Asleep, easy to rouse
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of 4 mg/h for intractable ischaemic leg pain that 
was not responding well to opioids. Subsequently 
his ischaemic leg was amputated under spinal 
anaesthesia with bupivacaine and 0.1 mg intrathecal 
morphine. Postoperatively his ketamine infusion 
was continued. Two hours after admission to the 
recovery unit he became unrousable (sedation score 
3). He remained spontaneously ventilating on 6 
litres per minute of oxygen with a respiratory rate of 
16 breaths per minute and an oxygen saturation of
96%. Following our APS protocol, naloxone 100 μg
was administered intravenously and the ketamine 
infusion was ceased, rapidly effecting a reversal of his 
sedation. He was closely monitored in the recovery 
unit for 24 hours postoperatively with no further 
sedation or respiratory depression. The ketamine 
infusion was recommenced and he was discharged to 
the vascular surgical ward with no further events.
7KHUHZHUHÀYHSDWLHQWVZKRKDGDVHGDWLRQVFRUH
of 2 (see Table 3). However their respiratory rate 
remained above six breaths per minute throughout 
WKHKRXUO\QXUVLQJREVHUYDWLRQVLQWKHÀUVWKRXUV
These cases included two opioid-tolerant patients. 
7KHÀUVWSDWLHQWZDVD\HDUROGPDQJLYHQPJ
intrathecal morphine at the time of spinal anaesthesia 
for leg amputation. Seven hours later, due to in-
adequate analgesia, he was ordered an intravenous 
morphine PCA and an intravenous ketamine infusion 
(initially at 4 mg/h increased to 8 mg/h one hour later). 
This was followed by 25 mg of oral amitriptyline 
12 hours after intrathecal morphine administration. 
Although a sedation score of 2 was not recorded 
until 25 hours after the intrathecal morphine dose,
the ward nursing staff had documented the patient’s
sedation score as “S” (sleeping) from 18 hours after 
administration. Thus  we cannot be sure that the 
patient did not have a sedation score of 2 at this 
earlier time, especially as he had not used the PCA 
VLQFH´6µZDVÀUVWQRWHG7RWDO3&$PRUSKLQHGRVHDW
that time was 16 mg. The nurses are supposed to wake 
the patient if asleep, but we suspect this sometimes 
did not happen.
The second opioid-tolerant patient with a sedation 
score of 2 was a 75-year-old man who received 
0.2 mg intrathecal morphine. Six hours later, again 
due to inadequate analgesia, the patient was given his 
usual slow-release oral morphine 60 mg (which would 
normally have been continued) and commenced on 
intravenous morphine PCA. Thirteen hours after 
the intrathecal morphine, the patient was noted to 
have a sedation score of 2. The total intravenous 
morphine used via PCA was 18 mg. The patient did 
not start morphine PCA again until 18 hours after 
the intrathecal morphine dose had been given, by 
which time his sedation score had returned to 0. 
Of the other three patients noted on the APS data 
sheets to have had sedation scores of 2, one had 
suddenly became sedated; this was noticed by his 
family and believed to be another of his transient 
ischaemic attacks (TIA). Another patient had a single 
recording of a sedation score of 2 at 13 hours after 
intrathecal morphine; all other sedation scores were 
1 or 0 and he had not been given any additional 
opioids or sedatives. The third patient was now 
deceased and his case notes could not be found 
for retrospective review, hence no information is 
available for the timing of the sedation score of 2 or 
administration of concurrent sedatives.
TABLE 2
Patient details and type of surgery
Patient age
    <70 years 171
    70 years or more 234
    Not recorded 4
Patient gender
    Male 272 (66.5%)
    Female 137 (33.5%)
Opioid-tolerant 28
    Given additional opioid within 24 hours 47
    Given a concurrent IV ketamine infusion 12
Ward after discharge from recovery
    HDU/ICU 77
    General vascular ward 324
    Other general surgical ward 8
Type of surgery
    Vascular surgery 347
    Orthopaedic surgery 50
    Urology 6
    General surgery 6
TABLE 3
Adverse effects
Respiratory depression (sedation score of 3) 1 (in recovery)






Mortality (not related to intrathecal morphine) 1
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7KHUH ZHUH D WRWDO RI  SDWLHQWV LGHQWLÀHG DV
opioid-tolerant (Table 4). Of these, only ten had 
WKHLURSLRLGVZLWKKHOGGXULQJWKHÀUVWKRXUVDIWHU
intrathecal morphine. The remaining 18 patients 
were given further opioids in the following manner: 
continuation of their usual opioid regimen of oral 
slow-release morphine, oral methadone or oxycodone; 
co-administration of intravenous morphine via PCA; 
or subcutaneous morphine administered by nursing 
staff as required for rescue analgesia. All cases of 
DGGLWLRQDO RSLRLG ZLWKLQ WKH ÀUVW  KRXUV ZHUH
approved and supervised by the APS. Only two 
patients had sedation score of 2 as reported above; 
no patient developed respiratory depression (by our 
GHÀQLWLRQLQWKHSRVWVXUJLFDOZDUG
were given general anaesthesia and intravenous 
opioids within the 24 hours after intrathecal morphine. 
One patient had intrathecal morphine followed by 
intravenous morphine PCA for abdominal aortic 
aneurysm repair, and hence required several days 
of ICU management. Three other patients also 
KDG VLJQLÀFDQW FDUGLDF FRPRUELGLWLHV ZKLFK OHG WR
admission into HDU/ICU postoperatively for more 
intensive monitoring and management. One of these 
three patients suffered a fatal cardiac arrest secondary 
to an arrhythmia within 24 hours postoperatively 
and resulted in the only mortality of this audit. He 
was not sedated prior to the cardiac arrest. Another 
14 vascular surgical patients were admitted to HDU/
ICU after intrathecal morphine for no apparent 
reason; we presume the anaesthetists concerned took 
extra precautions. 
A total of eight patients had undergone non-
vascular surgical procedures and were not admitted to 
HDU, ICU or the vascular surgery ward. This was a 
violation of the APS protocol in this institution. Five 
of these patients had orthopaedic joint replacement 
surgery, received no opioid analgesia within the 
ÀUVW  KRXUV DIWHU LQWUDWKHFDO PRUSKLQH DQG WKHLU
postoperative analgesia thereafter was managed by 
the surgical team. There was one patient who had 
undergone a radical prostatectomy with analgesia 
managed by intrathecal morphine and intravenous 
3&$PRUSKLQH DQG WKH ODVW SDWLHQW KDG VXSHUÀFLDO
leg surgery with no further requirements for opioid 
analgesia.
DISCUSSION
2XU DELOLW\ WR ORRN DW WKH HIÀFDF\ RI LQWUDWKHFDO
morphine as an adequate postsurgical analgesic 
technique is limited in this audit. Recordings of 
patient pain score as measured by verbal numerical 
rating scale or a patient’s verbal report in terms 
of “no pain, mild, moderate, or severe pain” were 
incomplete on many APS data sheets, which may 
SDUWLDOO\ UHÁHFW WKH SUREOHPV LQ WKH DVVHVVPHQW RI
pain in some elderly patients. Although we found that 
24.2% of non-vascular opioid-naïve patients received 
additional opioid compared with 4.4% of their 
vascular counterparts, we cannot conclude from our
VPDOOQXPEHUVWKDWQRQYDVFXODUSDWLHQWVKDGVLJQLÀ
cantly poorer analgesia after intrathecal morphine.
The incidence of nausea/vomiting and pruritus in 
our audit was 16.4% and 7.3% respectively. These are 
low compared with the incidence reported in other 
publications8,9, especially in that by Vercauteren and 
co-workers who recorded an incidence of up to 48% 
each for nausea and pruritus in obstetric practice11.
TABLE 4





Oral morphine slow-release 6 0
Oral oxycodone 2 4
Oral methadone 1 0
PCA morphine 6 18
Subcutaneous opioids 3 7
Ketamine infusion 2 2
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Of the patients who were opioid-naïve, 29 were 
given opioids for rescue analgesia within 24 hours after 
intrathecal morphine (Table 4). In all but one patient, 
this additional opioid administration was approved 
and supervised by the APS. In this one exception, the 
patient was given intramuscular pethidine without 
APS approval and in violation of APS protocols. 
Most cases of rescue opioid utilized intravenous 
morphine via PCA for post-orthopaedic joint replace-
ment surgery; however subcutaneous morphine or 
fentanyl, and oral oxycodone were also used. Of these 
opioid-naïve patients, 14 (4.4%) were vascular patients 
compared to 15 (24.2%) non-vascular patients.
A total of 77 patients were admitted to HDU/
ICU postoperatively following intrathecal morphine 
administration. Of these patients, 54 were non-
vascular postsurgical cases who could not be nursed 
in the general surgical wards according to our APS 
protocols, which do not allow patients given intrathecal 
morphine to go to wards where the nursing staff are 
not accredited for this technique.
The remaining 23 patients admitted to HDU/ICU 
had undergone vascular procedures. Of these patients, 
ÀYHKDGUHWXUQHGWRWKHRSHUDWLQJWKHDWUHIRUVXUJLFDO
control of postoperative bleeding. These patients 
Our lower incidence of these intrathecal morphine 
adverse effects may be due to the retrospective nature 
of this audit or it may be because of the number 
of elderly patients. A reduced incidence of these 
adverse effects in the elderly age group compared with 
the obstetric group has been found by other 
investigators8,12.
In the early 1980s, reports of delayed respiratory 
depression after intrathecal morphine in high doses 
of 0.5 mg to 2.0 mg began to emerge10. Since the mid-
1980s smaller doses of intrathecal morphine (0.1 mg 
to 0.2 mg) were used and reported to be safe and 
effective. However the debate continued. This led to
the publication by Gwirtz et al7 of a prospective 
seven-year audit of more than 5000 patients 
who received intrathecal opioid analgesia. Their 
protocol allowed for most of the 5000 patients to
be cared for in regular postsurgical wards. Only high-
risk patients such as the elderly (age >70 years),
those with poor pulmonary function, or those who
had undergone major thoracic or aortic surgery
ZHUHDGPLWWHGWRWKH,&87KHPDLQÀQGLQJRIWKHLU
study was a respiratory depression incidence of 3%,
which was detected by routine nursing observations 
that mandated hourly observations for 24 hours 
postoperatively. Gwirtz et al7 did not report on which 
of these patients had respiratory depression; it would 
be of interest to know whether these were the patients 
admitted to regular postsurgical wards, or those who 
received higher doses of intrathecal morphine, or the 
elderly or the respiratory compromised. 
We were able to show that our incidence of 
respiratory depression was much less than reported by 
Gwirtz et al7. In our audit of 409 cases, only one patient 
GHYHORSHG UHVSLUDWRU\ GHSUHVVLRQ E\ RXU GHÀQLWLRQ
This patient had a sedation score of 3 (unrousable), 
which was recognised at an early stage, prior to any 
drop in respiratory rate or oxygen desaturation, and 
easily treated with just a single dose of naloxone 
100 μg intravenously. That respiratory depression 
would occur at this early stage is probably unusual, 
given that the intrathecal morphine dose was small 
and that the onset of respiratory depression after 
intrathecal morphine is typically delayed by some 
hours. In addition, if respiratory depression did occur, 
it is likely to persist for some time. In this situation, 
repeat doses of naloxone would be required as the 
duration of its effect is relatively short. In our patient, 
re-sedation and a recurrence of respiratory depression 
did not occur and further doses of naloxone were 
not needed. Given the patient’s past history, it could 
also be possible that the patient may have suffered a 
transient ischaemic attack.
It has also been suggested that ketamine, an 
NMDA receptor antagonist, may increase the risk of
respiratory depression when given with opioid anal-
gesic agents. Concurrent administration of NMDA 
receptor antagonists and opioids in the rat resulted in
an increased incidence of respiratory depression 
compared with opioids alone13. However it may not
be possible to extrapolate these results to low-dose
ketamine administration in humans. Other than this
patient, where the diagnosis of intrathecal opioid-
induced respiratory depression is possibly question-
able, respiratory depression was not seen.
Of those patients who had sedation score of 2 but
no reduction in respiratory rate to less than 
six breaths/min, two were given intravenous morphine
via PCA because of inadequate analgesia. In one of 
these patients, an intravenous ketamine infusion and 
oral amitriptyline were also used as co-analgesics. 
As noted earlier, although a sedation score of 2 
ZDV ÀUVW GRFXPHQWHG  KRXUV DIWHU WKH LQWUDWKHFDO
morphine had been given, the patient could have 
been sedated for some hours before when the nurses 
scored him as “S”. By APS protocol, nursing staff are 
supposed to check if a sleeping patient can be roused, 
but this may not have been done. Furthermore, in
both of these cases, the initial PCA morphine bolus 
dose was not halved. APS guidelines note that 
this should be done until the peak rise of delayed 
respiratory depression has passed (16 hours) unless an 
increase is needed because of inadequate analgesia. 
Amitriptyline, given at a dose of 25 mg orally in the 
evening, may have been another contributing factor to
the sedation. 
We suggest caution in prescribing concurrent seda-
tives and co-analgesics to patients who have been 
given intrathecal morphine and, that if they are 
QHHGHG ORZHU GRVHV VKRXOG EH XVHG LQ WKH ÀUVW
instance. These doses can be increased later if found to
be inadequate and the patient known not to be seda-
ted. Vigilant nursing observations are required and 
nursing staff need to be aware of the important 
difference between normal sleep (when the patient is
easily rousable) and opioid-induced sedation. We have
now deleted the “S” from our sedation scoring 
system.
The situation regarding management of opioid-
tolerant patients given intrathecal morphine is 
SRWHQWLDOO\ GLIÀFXOW 7KH PDLQ DLP LV WR SURYLGH
adequate analgesia for the acute postoperative 
pain whilst preventing opioid withdrawal as well as 
respiratory depression. In our audit we found that 
three different strategies were used in these patients: 
administration of intrathecal morphine alone within 
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WKH ÀUVW  KRXUV GHSHQGLQJ RQ WKHLU SUHRSHUDWLYH
opioid dose); intrathecal morphine and continuation 
of regular oral opioid (most commonly slow-release 
morphine); and intrathecal morphine together with 
parenteral opioids. We cannot say from our audit 
and small patient numbers whether an advantage is 
offered by any one of the above strategies. It is clear 
however, that with strict monitoring guidelines in a 
regular postsurgical ward and with co-administration 
of only APS-approved opioid, those opioid-tolerant 
patients can be safely given intrathecal morphine as 
well as additional opioids.
A major problem in comparing studies of opioid-
induced respiratory depression, including after intra-
thecal morphine, is the lack of agreement for the best 
GHÀQLWLRQRIUHVSLUDWRU\GHSUHVVLRQ*ZLUW]HWDO7 used 
the criteria of increasing PaCO2. This has an important 
impact on interpreting results of different studies 
that look at the incidence of respiratory depression. 
6HYHUDO DUELWUDU\ LQGLFHV KDYH EHHQ XVHG WR GHÀQH
respiratory depression, such as respiratory rate less 
than 8 or 10 breaths/min, oxygen desaturation to less 
WKDQ  RU  UHGXFHG QDVDO DLU ÁRZ DUWHULDO
blood gas analysis for acidosis or hypercarbia with 
PaCO2 >50 mmHg; and sedation scores9,14,15. Regular 
SRVWVXUJLFDO ZDUGV ZRXOG ÀQG PRQLWRULQJ QDVDO
DLUÁRZ DQG DUWHULDO EORRG JDV DQDO\VHV LPSUDFWLFDO
Oxygen desaturation as measured by pulse oximetry 
has several problems which make it unreliable as a 
sign of respiratory depression, especially if the patient 
is receiving supplemental oxygen. Continuous pulse 
oximetry monitoring would also be required. Sedation 
has been shown to be a more reliable earlier sign of 
depression than a decrease in respiratory rate16. Hence 
we rely primarily on sedation scores as our measure of 
respiratory depression.
In summary, our regimen for the management 
of patients given intrathecal morphine appears to 
be safe for our predominantly elderly patients in a 
regular postsurgical ward provided there is a strict 
adherence to protocols. These protocols should in-
clude a minimum of the following: registered nurses 
appropriately trained and accredited by the APS; 
hourly nursing observations of sedation score, res-
piratory rate and other vital signs for 24 hours after 
intrathecal morphine administration; an intravenous 
naloxone standing order for reversal of respiratory 
depression; 24-hour cover provided by on-site anaes-
thetists; and no further opioid administration within 
WKHÀUVWKRXUVXQOHVVDSSURYHGE\WKH$36
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